20230824-招银国际-石药集团-01093.HK-Steady_finished_drug_sales_5页_1mb

报告摘要

CSPC Pharmaceutical Group (1093 HK) 1H23 Performance and Outlook

Company Overview: CSPC Pharmaceutical Group issued a company update for the first half of 2023, providing financial results and strategic initiatives. The report covers revenue growth, product performance, research and development, new product pipelines, and valuation.

Key Financial Performance (1H23)

Revenue: Increased by 3.0% YoY to RMB 16.08 billion.
Attributable Net Profit: Remained flat YoY at RMB 2.97 billion (adjusted profit up 3.0% YoY to RMB 3.16 billion).
Finished Drug Sales: Grew 5.2% YoY to RMB 12.93 billion, led by nervous system sales (+17.5% YoY).
Segments: Oncology sales decreased 26.0% YoY due to Keaili price adjustments; vitamin C sales fell 25.7%; antibiotics increased 19.1%; functional food revenue grew 3.5% YoY despite caffeine price declines.
Profitability: Gross margin declined 2.7 ppt to 69.9%, driven by lower prices. R&D expenses rose 22.3% YoY (RMB 2.30 billion), while SG&A ratio improved to 33.8%.

New Product Developments and Pipeline

Strong Growth: NBP drove nervous system sales; new products like Duoenda (anti-tumor nanodrug) and Anfulike (lipid-based amphotericin B) show potential for rapid ramp-up.
Upcoming Launches: Expect over 30 new products in the next three years, including JMT103, irinotecan liposome, and Mingfule.
Pipeline Targets: Duoenda, glumetinib, and others aim for NRDL approval in 2024. By 2025, focus on oncology and specialty drugs could drive revenue to over RMB 1 billion from new products.

Valuation and Recommendation

Stock Rating: Maintain BUY with target price HK$8.08 (down 43.5% from prior TP), reflecting a challenging market outlook.
Analyst Views: Revised DCF-based valuation due to slower growth in H23E and 24E forecasts, with potential downside.
Comparable Metrics: P/E ratio decreases from 14.2x in 2022 to 8.9x in 2025E, indicating compressed valuations.